DE60324700D1 - Zelltod-induzierender wirkstoff - Google Patents

Zelltod-induzierender wirkstoff

Info

Publication number
DE60324700D1
DE60324700D1 DE60324700T DE60324700T DE60324700D1 DE 60324700 D1 DE60324700 D1 DE 60324700D1 DE 60324700 T DE60324700 T DE 60324700T DE 60324700 T DE60324700 T DE 60324700T DE 60324700 D1 DE60324700 D1 DE 60324700D1
Authority
DE
Germany
Prior art keywords
antibody
cell
tod
active substance
cell death
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60324700T
Other languages
English (en)
Inventor
Shuji Ozaki
Masahiro Abe
Masayuki Tsuchiya
Naoki Kimura
Shigeto Kawai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE60324700D1 publication Critical patent/DE60324700D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
DE60324700T 2002-10-11 2003-10-10 Zelltod-induzierender wirkstoff Expired - Lifetime DE60324700D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002299289 2002-10-11
PCT/JP2003/013063 WO2004033499A1 (ja) 2002-10-11 2003-10-10 細胞死誘導剤

Publications (1)

Publication Number Publication Date
DE60324700D1 true DE60324700D1 (de) 2008-12-24

Family

ID=32089339

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60324700T Expired - Lifetime DE60324700D1 (de) 2002-10-11 2003-10-10 Zelltod-induzierender wirkstoff

Country Status (7)

Country Link
US (1) US8158385B2 (de)
EP (1) EP1561759B9 (de)
JP (2) JPWO2004033499A1 (de)
AT (1) ATE414105T1 (de)
AU (1) AU2003271175A1 (de)
DE (1) DE60324700D1 (de)
WO (1) WO2004033499A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
CN1308448C (zh) 2000-10-20 2007-04-04 中外制药株式会社 低分子化的tpo激动剂抗体
EP2351838A1 (de) * 2000-10-20 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Vernetzende, agonistische Antikörper
ATE414105T1 (de) 2002-10-11 2008-11-15 Chugai Pharmaceutical Co Ltd Zelltod-induzierender wirkstoff
JP2004279086A (ja) * 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
JPWO2004087763A1 (ja) * 2003-03-31 2006-07-27 中外製薬株式会社 Ｃｄ２２に対する改変抗体およびその利用
TW200530269A (en) * 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
AU2004297109A1 (en) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha Cell death inducing agent
WO2005056602A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha アゴニスト活性を有する改変抗体のスクリーニング方法
JPWO2005056605A1 (ja) * 2003-12-12 2007-12-06 中外製薬株式会社 ３量体以上の受容体を認識する改変抗体
JP4799405B2 (ja) * 2004-04-09 2011-10-26 中外製薬株式会社 細胞死誘導剤
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
WO2006123724A1 (ja) * 2005-05-18 2006-11-23 The University Of Tokushima 抗hla抗体を利用した新規医薬品
AU2006256041B2 (en) 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
US20090028854A1 (en) * 2005-06-10 2009-01-29 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 SITE-DIRECTED MUTANT
KR101360671B1 (ko) 2005-06-10 2014-02-07 추가이 세이야쿠 가부시키가이샤 ｓｃ（Ｆｖ）２를 함유하는 의약조성물
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
MX2009000487A (es) * 2006-07-13 2009-01-27 Chugai Pharmaceutical Co Ltd Inductor de muerte celular.
CL2008000719A1 (es) * 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
JPWO2009066655A1 (ja) * 2007-11-19 2011-04-07 国立大学法人 鹿児島大学 アポトーシス誘導能を有するヒト抗体
TW201118166A (en) * 2009-09-24 2011-06-01 Chugai Pharmaceutical Co Ltd HLA class I-recognizing antibodies
CA2861003C (en) * 2012-01-13 2023-03-28 Julius-Maximilians-Universitat Wurzburg Dual antigen-induced bipartite functional complementation
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
KR102441231B1 (ko) 2013-09-27 2022-09-06 추가이 세이야쿠 가부시키가이샤 폴리펩티드 이종 다량체의 제조방법
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP2727112B2 (ja) 1988-04-26 1998-03-11 コニカ株式会社 安定なペルオキシダーゼ組成物及び安定な抗体組成物
US5077216A (en) 1988-07-06 1991-12-31 The Trustees Of Dartmouth College Monoclonal antibodies specific for a human mononculear phagocyte-specific antigen
JPH0341033A (ja) 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
US5223241A (en) 1990-10-01 1993-06-29 The General Hospital Corporation Method for early detection of allograft rejection
EP0562125A4 (de) 1991-10-11 1994-03-18 Toray Industries Antikörperzusammensetzungen.
EP0627932B1 (de) 1992-11-04 2002-05-08 City Of Hope Antikörperkonstrukte
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
CA2117477C (en) 1992-12-11 2001-06-12 Peter S. Mezes Multivalent single chain antibodies
US5780021A (en) 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
US5747654A (en) * 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
ZA946767B (en) 1993-09-03 1995-04-03 Chugai Pharmaceutical Co Ltd Monocional antibodies having property of causing apoptosis.
JP3554355B2 (ja) 1994-03-03 2004-08-18 中外製薬株式会社 Ｉｌ−６オートクライン増殖性ヒト骨髄腫細胞株
US6719972B1 (en) 1994-06-03 2004-04-13 Repligen Corporation Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US8771694B2 (en) 1994-08-12 2014-07-08 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6451523B1 (en) 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
US5690935A (en) 1995-01-13 1997-11-25 Regents Of The University Of Minnesota Biotherapy of cancer by targeting TP-3/P80
BR9604884A (pt) 1995-02-28 1998-05-19 Procter & Gamble Preparação de produtos de bebida não carbonatada com estabilidade microbiana superior
US6013067A (en) 1995-06-07 2000-01-11 Zymogenetics, Inc. Methods for increasing hematopoietic cells
AU6113396A (en) 1995-06-14 1997-01-15 Regents Of The University Of California, The Novel high affinity human antibodies to tumor antigens
EP1619250B1 (de) 1996-01-08 2009-11-25 Genentech, Inc. OB Rezeptor-Variante und Liganden
FR2745008A1 (fr) 1996-02-20 1997-08-22 Ass Pour Le Dev De La Rech En Recepteur nucleaire de glucocorticoides modifie, fragments d'adn codant pour ledit recepteur et procedes dans lesquels ils sont mis en oeuvre
AU2232597A (en) 1996-03-06 1997-09-22 Chugai Seiyaku Kabushiki Kaisha Method of screening apoptosis inducing substances
ATE316792T1 (de) 1996-05-09 2006-02-15 Pharma Pacific Pty Ltd Stimulierung wirtseigener abwehrmechanismen gegen krebs
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6323000B2 (en) 1996-12-20 2001-11-27 Clark A. Briggs Variant human α7 acetylcholine receptor subunit, and methods of production and uses thereof
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
WO1999002567A2 (en) 1997-07-08 1999-01-21 Board Of Regents, The University Of Texas System Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
PL339265A1 (en) 1997-09-11 2000-12-04 Chugai Pharmaceutical Co Ltd Apoptose causing monoclonal antibody
US7531643B2 (en) 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
US7081360B2 (en) 1998-07-28 2006-07-25 Cadus Technologies, Inc. Expression of G protein-coupled receptors with altered ligand binding and/or coupling properties
US20050220787A1 (en) 2002-11-07 2005-10-06 Lobo Peter I Naturally occuring IgM antibodies that bind to lymphocytes
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
US7442776B2 (en) 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US20020028178A1 (en) 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
TWI242043B (en) 2000-03-10 2005-10-21 Chugai Pharmaceutical Co Ltd Polypeptide inducing apoptosis
US20040058393A1 (en) 2000-04-17 2004-03-25 Naoshi Fukishima Agonist antibodies
PT1314437E (pt) 2000-08-11 2014-08-29 Chugai Pharmaceutical Co Ltd Preparações estabilizadas contendo anticorpo
AU2002210917B2 (en) 2000-10-20 2006-05-18 Chugai Seiyaku Kabushiki Kaisha Degraded TPO agonist antibody
CN1308448C (zh) 2000-10-20 2007-04-04 中外制药株式会社 低分子化的tpo激动剂抗体
EP2351838A1 (de) 2000-10-20 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Vernetzende, agonistische Antikörper
EP1327681A4 (de) 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Degradierte Agonisten Antikörper
WO2002094880A1 (en) 2001-05-18 2002-11-28 Kirin Beer Kabushiki Kaisha Anti-trail-r antibodies
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
JP3665324B2 (ja) 2001-10-15 2005-06-29 麒麟麦酒株式会社 抗ｈｌａ−ｄｒ抗体
JP2005507659A (ja) 2001-10-15 2005-03-24 イミューノメディクス、インコーポレイテッド 直接ターゲッティング結合タンパク質
KR101080021B1 (ko) 2002-02-14 2011-11-04 추가이 세이야쿠 가부시키가이샤 항체함유 용액제제
EP1485130A4 (de) 2002-02-21 2006-11-22 Univ Duke Reagenzien und behandlungsverfahren für autoimmunkrankheiten
JP4386741B2 (ja) 2002-04-15 2009-12-16 中外製薬株式会社 ｓｃＤｂライブラリーの作成方法
JP2004086862A (ja) 2002-05-31 2004-03-18 Celestar Lexico-Sciences Inc タンパク質相互作用情報処理装置、タンパク質相互作用情報処理方法、プログラム、および、記録媒体
US20050130224A1 (en) 2002-05-31 2005-06-16 Celestar Lexico- Sciences, Inc. Interaction predicting device
AU2003243651B2 (en) 2002-06-17 2008-10-16 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Specificity grafting of a murine antibody onto a human framework
US20040101915A1 (en) 2002-06-18 2004-05-27 Irm Llc, A Delaware Limited Liability Company Diagnosis and treatment of chemoresistant tumors
US7115373B2 (en) 2002-06-27 2006-10-03 Genox Research, Inc. Method of testing for atopic dermatitis by measuring expression of the NOR-1 gene
WO2005004912A1 (en) 2003-07-11 2005-01-20 Oncotherapy Science, Inc. Method for treating synovial sarcoma
ATE414105T1 (de) 2002-10-11 2008-11-15 Chugai Pharmaceutical Co Ltd Zelltod-induzierender wirkstoff
AU2003301654A1 (en) 2002-10-22 2004-05-13 Dainippon Pharmaceutical Co., Ltd. Stabilized composition
JP2004279086A (ja) 2003-03-13 2004-10-07 Konica Minolta Holdings Inc 放射線画像変換パネル及び放射線画像変換パネルの製造方法
JPWO2004087763A1 (ja) 2003-03-31 2006-07-27 中外製薬株式会社 Ｃｄ２２に対する改変抗体およびその利用
KR20060121150A (ko) 2003-11-11 2006-11-28 추가이 세이야쿠 가부시키가이샤 인간화 항-ｃｄ47 항체
TW200530266A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Method of reinforcing antibody activity
JPWO2005056605A1 (ja) 2003-12-12 2007-12-06 中外製薬株式会社 ３量体以上の受容体を認識する改変抗体
WO2005056602A1 (ja) 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha アゴニスト活性を有する改変抗体のスクリーニング方法
AU2004297109A1 (en) 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha Cell death inducing agent
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
KR20070010046A (ko) 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
JP4799405B2 (ja) 2004-04-09 2011-10-26 中外製薬株式会社 細胞死誘導剤
US9493569B2 (en) 2005-03-31 2016-11-15 Chugai Seiyaku Kabushiki Kaisha Structural isomers of sc(Fv)2
WO2006123724A1 (ja) 2005-05-18 2006-11-23 The University Of Tokushima 抗hla抗体を利用した新規医薬品
US20090028854A1 (en) 2005-06-10 2009-01-29 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 SITE-DIRECTED MUTANT
AU2006256041B2 (en) 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
WO2007136892A2 (en) 2006-02-02 2007-11-29 The General Hospital Corporation Engineered antibody-stress protein fusions
MX2009000487A (es) 2006-07-13 2009-01-27 Chugai Pharmaceutical Co Ltd Inductor de muerte celular.
AU2007285217B2 (en) 2006-08-14 2013-02-07 Forerunner Pharma Research Co., Ltd Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
CL2008000719A1 (es) 2007-03-12 2008-09-05 Univ Tokushima Chugai Seiyaku Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
MX2010006395A (es) 2007-12-21 2010-07-01 Hoffmann La Roche Formulacion de anticuerpos.

Also Published As

Publication number Publication date
EP1561759B1 (de) 2008-11-12
JPWO2004033499A1 (ja) 2006-02-09
ATE414105T1 (de) 2008-11-15
JP2010155841A (ja) 2010-07-15
US8158385B2 (en) 2012-04-17
WO2004033499A1 (ja) 2004-04-22
AU2003271175A1 (en) 2004-05-04
EP1561759A4 (de) 2006-05-31
EP1561759B9 (de) 2009-08-26
EP1561759A1 (de) 2005-08-10
US20060275301A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
DE60324700D1 (de) Zelltod-induzierender wirkstoff
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
EA200500520A1 (ru) Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов
EA200600594A1 (ru) Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения
PT1315520E (pt) Utilizacao de anticorpos trifuncionais biespecificos e triespecificos para tratamento de ascites malignas
EA200100315A1 (ru) Простые тетрагидропиридовые эфиры
EA200301117A1 (ru) Антитела против vla-1
CO5580797A2 (es) Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos
ES2559763T3 (es) Anticuerpo humano específico de CD3 con propiedades inmunosupresoras
DE69433663D1 (de) Antikörper gegen menschliches prostatspezifisches drüsenkallikrein
EA200800812A1 (ru) Композиции антитела против cd3
EA200501286A1 (ru) МОЛЕКУЛЫ АНТИТЕЛ СО СПЕЦИФИЧНОСТЬЮ К ЧЕЛОВЕЧЕСКОМУ IL-1β
SG153829A1 (en) Identifying virally infected and vaccinated organisms
EA200201214A1 (ru) Замещенные тиоацетамиды
EA200800199A1 (ru) Способ получения олефина и/или простого эфира
EA200970923A1 (ru) АНТИ-EpСАМ АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
DK1755659T3 (da) Anvendelse af anti-alfa5beta1-antistoffer til inhibering af kræftcelleproliferation
EA200201252A1 (ru) Соединения, эффективные в качестве агонистов э2 - адренорецептора и ингибиторов фосфодиэстеразы pde4
DE69932812D1 (de) Epitope in der viralen hüllproteine und spezifische antikörper gegen diese epitope: verwendung für die detektion von hcv viralantigene im empfängergewebe
MX2021002299A (es) Anticuerpos de anti-cd33 y metodos para usarlos.
EA200401628A1 (ru) Ингибиторы пептидной деформилазы
SE0000675D0 (sv) Monoclonal antibodies
ATE467128T1 (de) Kolloidale metallkonjugate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition